PHILADELPHIA, May 8, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2013. The net loss (including non-cash effects) was approximately $3,611,000 or $(0.02) per share as compared to a net loss of $2,308,000 or ($0.02) per share for the same three month period in 2012. This First Quarter-to-Quarter increase in net loss of approximately $1,303,000 was predominantly caused by:
- an increase of approximately $671,000 related to continued efforts to seek FDA approval of the Ampligen® NDA for Chronic Fatigue Syndrome and preparations for commercial manufacturing at our New Brunswick, NJ facility;
- approximately $95,000 in higher non-cash stock compensation to strategic consultants supporting the overall Ampligen® commercialization effort; and
- a decrease of approximately $642,000 from sales of New Jersey State Net Operating Loss carry forwards.